Wong C.,University Hospital of Hvidovre |
Pedersen S.A.,Hvidovre University Hospital Denmark |
Kristensen B.B.,Hvidovre University Hospital Denmark |
Gosvig K.,Hvidovre University Hospital Denmark |
Sonne-Holm S.,University Hospital of Hvidovre
Spine | Year: 2015
Study Design. A prospective, randomized triple-blinded crossover design treating with either botulinum toxin A (BXT) or saline (NaCl). Objective. To examine the efficacy of BTX treatment in cerebral palsy scoliosis (CPS). Summary of Background Data. Intramuscular injections with BTX have been used off label in treating CPS. 1 prospective study has been conducted, demonstrating in both radiological and clinical improvement, whereas showing no side effects or complications. Methods. Subjects (brace-treated CPS between 2 and 18 yr) were injected using ultrasonic-guidance with either NaCl or BTX in selected spine muscles with 6 mo intervals (block randomization, sealed envelope). Radiographs of the spine and clinical follow-up were captured before and 6 weeks after each injection. Primary outcome parameter was radiological change in Cobb angle, where a 7° change was regarded as an effect (1 SD). Radiological parameters were measured before and 6 weeks after treatment by 3 experienced doctors separately. Moreover, clinical results were evaluated by the pediatric quality of life score and systematic open questioning of the parents about the child's wellbeing. Subjects, researchers, and monitors were blinded during the trial. Appropriate permissions (2008- 004584-19) and no funding were obtained. Results. 16 cerebral palsy patients (GFMCS III-V) with CPS were consecutively included, whereas 6 patients were excluded. There were no drop-outs to follow-up, but 1 possible serious adverse event of pneumonia resulting in death was recorded and the study was terminated. No significant radiological or clinical changes were detected when compared with NaCl injections using Wilcoxon matched pair signed-rank test. Conclusion. No positive radiological or clinical effects were demonstrated by this treatment, except for the parent's initial subjective but positive appraisal of the effect. However, the study was terminated due to 1 possible severe adverse event and scheduled numbers needed to treat (hence power) were not reached. © 2015 Wolters Kluwer Health, Inc. All rights reserved.